J. Goldman & Co’s Immunic IMUX Stock Holding History

J. Goldman & Co’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,358	Closed	-$75K	–	425
2022 Q3	$75K	Sell	2,358 -675	-22%	-$28.3K	﹤0.01%	346
2022 Q2	$105K	Sell	3,033 -7,117	-70%	-$456K	0.01%	319
2022 Q1	$1.15M	Buy	+10,150	New	+$1.17M	0.05%	245

Other funds holding IMUX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

J. Goldman & Co's IMUX Position: Q4 2022 in Review

J. Goldman & Co sold out of Immunic (IMUX) in Q4 2022, closing a stake of 2,358 shares — an estimated $75K sold.

J. Goldman & Co first reported a position in IMUX in Q1 2022 and held it in 3 quarters. The position peaked at $1.15M in Q1 2022. 58 funds tracked by Wall St. Rank hold IMUX as of Q4 2022.

J. Goldman & Co reported no remaining Immunic position as of Q4 2022 after selling out during the quarter.
J. Goldman & Co sold 2,358 Immunic shares in Q4 2022, an estimated $75K.
J. Goldman & Co first reported a position in Immunic in Q1 2022 and held it in 3 quarters.
J. Goldman & Co's Immunic position peaked at $1.15M in Q1 2022.
58 funds tracked by Wall St. Rank held Immunic as of Q4 2022.

Based on J. Goldman & Co's 13F filing for Q4 2022, filed 14 Feb 2023.